Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy

Yannelli, John R.; Crumpacker, Dina B.; Good, Robert W.; Friddell, Colleen D.; Poston, R M; Horton, Sharon; Maleckar, James R.; Oldham, Robert K.

doi:10.1016/0022-1759(90)90303-d

Cited by 22 publications

(4 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased precursor frequencies of tumour specific cytotoxic T lymphocytes in some tumours in comparison with peripheral blood mononuclear cells (PBMC) strengthens this hypothesis.' However, although tumour infiltrating lymphocytes can effectively kill autologous tumour cells in vitro stimulation and expansion,4 5 proliferative and cytotoxic responses of freshly isolated tumour infiltrating lymphocytes are frequently impaired. 3 6 In tumour bearing mice it has been demonstrated that a loss of two according to the procedure as described by Merchenthaler.22 Briefly, after a pre-incubation in normal saline solution, both antibodies were incubated simultaneously in the appropriate dilution.…”

Section: Conclusion-the Frequency Of Tcr-c'mentioning

confidence: 99%

T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma.

Mulder

Bloemena

Stukart

et al. 1997

Gut

View full text Add to dashboard Cite

Section: Conclusion-the Frequency Of Tcr-c'mentioning

confidence: 99%

T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma.

Mulder

Bloemena

Stukart

et al. 1997

Gut

View full text Add to dashboard Cite

“…10 Few differences were noted even though the criteria for successful initiation in the present study was 1.0 3 10 9 cells versus 5.0 3 10 8 cells in the previous study, and more cultures were stimulated initially with OKT3 in the current series. 27 The interval from initiation of TIL to treatment in this series was 88 days, which is somewhat longer than the 70-80 day range of our previous series. 10,14 One of the complicating factors for the current series was the type of bioreactor used (i.e., small or large).…”

Section: Discussionmentioning

confidence: 83%

Characterization of Human Tumor-Infiltrating Lymphocytes Expanded in Hollow-Fiber Bioreactors for Immunotherapy of Cancer

Malone

Schiltz

Mackintosh

et al. 2001

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

We attempted to grow tumor-infiltrating lymphocytes (TIL) from 34 fresh tumors of eight different histologies using flasks for the initiation phase and hollow fiber bioreactors to expand TIL to therapeutic numbers. Overall success rate was 76% (26/34) including melanoma (9/14, 64%) and renal cell carcinoma (11/11, 100%). The mean number of days required to reach successful initiation (1 x 10(9) TIL) for all tumor types was 29 +/- 16 days (mean +/- S.D.). Therapeutic doses of TIL required an average of 88 +/- 23 days (initiation plus expansion) with an average TIL number of 3.2 x 10(10) +/- 2.8 x 10(10). TIL phenotype was predominantly CD4+ in 53% (16/30) and CD8+ in 47% (14/30), renal cell carcinoma samples accounted for 12/14 of the predominantly CD8+ TIL. Cells bearing the natural killer (NK) phenotype represented only 0-7% of TIL while LAK phenotype represented 0-68% (mean 11 +/- 15%); LAK was the predominant phenotype in one patient with kidney cancer. Cytotoxicity tests showed consistent NK and LAK activity in addition to cytolysis of autologous tumor. Autologous tumor cell restricted cytolysis was noted for three TIL cultures. The overall success rate and characteristics of TIL were similar to our results with TIL expanded in semi-permeable plastic bags. This work confirms that hollow-fiber bioreactors are a suitable alternative to semi-permeable bags and roller bottle systems for the expansion of human TIL for therapeutic use in cancer patients.

show abstract

“…Previous TIL studies demonstrated a growth advantage when the cells were exposed to anti-CD3. 38 In addition, all cultures were grown in the presence of 7000 IU/mL of IL-2. The TIL cultures were established, maintained, and expanded as described previously.…”

Section: Functional Reactivity Of Til Grown From Solid Tumor Biopsiesmentioning

confidence: 99%

“…The final products were counted, assessed for viability by trypan blue exclusion analysis, and prepared for cell culture. The cells were placed in culture by standard TIL methodology as described previously, 37 except that the plates were coated with 1 mg/well of anti-CD3 monoclonal antibody 38 to stimulate T-cell proliferation. The TIL cultures were established at 1 3 10 6 TIL per well in 24-well sterile cell culture plates in medium containing 7000 IU of recombinant interleukin-2 (IL-2).…”

Section: Til Cultures: Solid Tumor and Pleural Fluid Samplesmentioning

confidence: 99%

Growth and Functional Reactivity of Lymphocytes Obtained from Three Anatomic Compartments in Patients with Non–Small-Cell Lung Cancer (NSCLC)

Yannelli

Hirscowitz

Wroblewski

2003

Cancer Biotherapy and Radiopharmaceuticals

Self Cite

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) claims the lives of both men and women worldwide. In this study, we describe the ability to expand lymphocytes from solid tumor biopsies, pleural fluid, and peripheral blood of patients with NSCLC. While lymphocytes readily expanded from both solid biopsies and pleural fluids, the incidence of obtaining tumor-specific lymphocytes was low. Specific cytolytic and/or cytokine-releasing activity was observed in tumor-infiltrating lymphocytes (TIL) from 3/15 solid tumor biopsies (20%) and 2 of 4 pleural fluid samples (50%). Two of the CTL derived from solid tumor were cytolytic, one being HLA-A2 restricted while the other was either restricted at HLA-A30 or - B18. One of the pleural fluid cytotoxic T lymphocyte (CTL) was also HLA-A2 restricted. Peripheral blood from NSCLC patients was studied using mixed lymphocyte tumor cell cultures (MLTC) as reported previously. Peripheral blood lymphocytes were cultured with allogeneic NSCLC-TC line 29.7, which expressed by gene transfer the lymphocyte costimulatory molecule CD80. Of 9 HLA-A2 patient samples tested, 8 gave rise to lymphocytes, which lysed NSCLC tumor cells expressing HLA-A2 in an major histocompatibility complex (MHC)-restricted fashion. While specific CTL can be generated from all anatomic sites, for clinical trials peripheral blood appears to be the site of choice for obtaining specific precursors.

show abstract

Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy

Cited by 22 publications

References 28 publications

T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma.

T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma.

Characterization of Human Tumor-Infiltrating Lymphocytes Expanded in Hollow-Fiber Bioreactors for Immunotherapy of Cancer

Growth and Functional Reactivity of Lymphocytes Obtained from Three Anatomic Compartments in Patients with Non–Small-Cell Lung Cancer (NSCLC)

Contact Info

Product

Resources

About